Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — InfuSystem Holdings — Investor Presentation (December 2019)
18 slides from Infusystems's investor presentation, Dec 10, 2019
Slide 1: InfuSystem Investor Presentation December 2019
CinfuSystem INFUSION MADE EASY“ INVESTOR PRESENTATION December 2019
Slide 2: Services and Solutions Facilitating Outpatient Care
“Services and Solutions Facilitating Outpatient Care” Exceptional Services, Products and People Devoted to Patient Wellness; currently serving more than 6,000 sites of care Our services improve access to quality medical equipment, benefiting providers and patients, and lowering the total cost of car
Slide 3: Forward-Looking Statement / Non-GAAP Measures
Forward-Looking Statement / Non-GAAP Measures Forward.ooking Statement Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A ofthe Securities Act of 1933, asamended, ‘and Section 21€ ofthe Securities Exchange Act of 1934, as amended, sucha
Slide 4: InfuSystem Key Facts At-a-Glance
InfuSystem Key Facts At-a-Glance 33 Years [1,000,000+f 81,000 In Business Total Patients Service DEVICES IN FLEET 8 out of 10 TopHospimais) | Nearly 650 Nationwide Third-Party Payer Contracts *Source: US News & World Report, Best Hospitals. July 2019 o~ Safe. Smart. Trusted (InfuSystem
Slide 5: Two Proven Business Platforms
Two Proven Business Platforms DME SUPPORT SERVICES INTEGRATED THERAPY SERVICE Duplicable, lower margin, high turn model Unique, high margin, high service model (concierge services) (turnkey therapies) + Supply the DME equipment + supply the consumables + Equip/supplies logistics * Hospital/clinic cu
Slide 6: Platforms Leveraged into Multiple Therapies
Platforms Leveraged into Multiple Therapies Future Growth From Market Share Gains and From Adding New Therapies DME SUPPORT SERVICES INTEGRATED THERAPY SERVICES Duplicable, lower margin, high turn model ff Unique, high margin, high service model (concierge services) (turnkey therapies) Home Health C
Slide 7: % Cash Collected by payer 2018
% Cash Collected by payer 2018 Commercial payer: 40.1% Private Pay 2.9% No single payer \ im an 135% Hospital / Alternate Site Direct Pay 53.8% ~ 6000 Direct Pay Hospital and Alternate Site Customers Medicaid 1.2% 100% Direct Customer Pay * Third party payer (nearly 650 contracts) + Hospital/clinic
Slide 8: Mainstream Distribution Unique Clinic-to-Home
Mainstream Distribution Unique Clinic-to-Home Deliver equipment and supplies > High Service/High Value “Turnkey” model Order/delivery logistics Limited services by design > Logistics manufacturer-to-clinic-to-patient > 24x7 nursing support Standard direct (invoice) billing > Specialized 3” party bil
Slide 9: Competitive Advantages
Competitive Advantages Deep Moats Based On Unique Focus, Nationwide Scale, and Cultivated DME Payer Contracts Leveraging High-Service Orientation of Company to Win Concierge Opportunities Over 6,000 customers, Complete coverage of North America Nursing staff that provides continuous 24/7 support to
Slide 10: Oncology: Recent Market Share Gains
Oncology: Recent Market Share Gains 2018: LEADING ELASTOMERIC COMPETITOR 2019: LEADING DIRECT COMPETITOR + FDA stopped import of largest elastomeric *+ Lastand largest direct electronic pump competitor manufacturer elected to exit third-party payer model * Clinicians forced to migrate to alternative
Slide 11: Oncology: Significant Market Share Gains
Oncology: Significant Market Share Gains Oncology Outpatient Clinics and Third-Party Payer Contracts 2200 2180 ted are comes “792019 and F202 are manogement estimates ‘+ 2018: Largest elastomeric provider + 2019: Largest market competitor exiting market subject to FDA recall Creating further growth
Slide 12: Financial Results
Financial Results Through Q3 2018 Through Q3 2019 Revenue $49.6 million $59.4 million AEBITDA $10.0 million $12.8 million Op Cash Flow $8.2 million $9.5 million —
Slide 13: Financial Trend & Current Targets
Financial Trend & Current Targets Net Revenues & AEBITDA Cash Flows from Operations ss seo 85 suse ses bead $79.0 $70 | $65.7 $65.5, $67.1 E = baal $34 - | (i “se : : H fas 0 20 it = s ses 25% $10 Sao La % ra oo 10% rots roi? roots ants rya00* zoiea 017A” aoa aoisr aon Notes: FY 2019 and £Y2020 are
Slide 14: Driving Shareholder Value
Driving Shareholder Value 4 1940) oncology ‘November ‘Gains Begin 200 2017 me sco New Eo WEM AMS JASONDWFMAMI J ASONODWFMAMJSASOND 2017 2018 antes “+ Tumnaround(S€ 1609 & ASC606):Officeofthe |* INFUrepurchases 14%4of shares outstanding | + Significant market share gainsin oncology President sharehol
Slide 15: Looking Ahead
Looking Ahead Focus on strategic offerings and long-term, sustainable growth opportunities Talent New Growth Manufacturer Device Capital Acquisition Strategy Partnerships Utilization Allocation Attract & retain Leverage existing Access to the latest. © Smart device Maximize value the best talent to
Slide 16: As of December 2, 2019
As of December 2, 2019 Stock Price | 52 Week Range $8.14 $3.33 - $8.42 ENTERPRISE VALUE $199 Million ‘Stock Performance ‘Stock repurchase: 163% (annualized: 121%) $3.10 July 31, 2018; $8.14 December 3, 2019 YTD: 135% (annualized: 146%) $3.44 December 31, 2018; $8.14 December 3,2019
Slide 17: Patient is at the center of everything we do (CEO quote)
Slide 18: InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. + IR Contact Info: + Joe Dorame, Managing Partner + Lytham Partners, LLC * 602-889-9700 + dorame@lythampartners.com
InfuSystem Holdings — Investor Presentation (December 2019) on 6ix